`
`
`
`
`
`NOVARTIS PHARMACEUTICALS
`CORPORATION and NOVARTIS AG,
`
`
`Plaintiffs,
`
`
`v.
`
`
`MYLAN PHARMACEUTICALS INC.
`
`
`
`Defendant.
`
`
`
`
`
`
`
`
`C.A. No. _____________
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`Plaintiffs Novartis Pharmaceuticals Corporation and Novartis AG (hereinafter
`
`“Plaintiffs”), for their Complaint against defendant Mylan Pharmaceuticals Inc. allege as
`
`follows:
`
`1.
`
`2.
`
`NATURE OF ACTION
`
`This is an action for patent infringement.
`
`PARTIES
`
`Plaintiff Novartis Pharmaceuticals Corporation (“NPC”) is a corporation
`
`organized and existing under the laws of the State of Delaware, having a principal place of
`
`business at One Health Plaza, East Hanover, New Jersey 07936.
`
`3.
`
`Plaintiff Novartis AG (“Novartis AG”) is a corporation organized and
`
`existing under the laws of Switzerland, having an office and place of business at Lichtstrasse 35,
`
`CH-4056 Basel, Switzerland.
`
`
`ME1 24559871v.1
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 2 of 10 PageID #: 2
`
`
`
`4.
`
`On information and belief, defendant Mylan Pharmaceuticals Inc.
`
`(“Mylan”) is a corporation organized and existing under the laws of the State of West Virginia,
`
`having a place of business at 781 Chestnut Ridge Road, Morgantown, West Virginia 26505.
`
`Upon information and belief, defendant Mylan directly or indirectly develops, manufactures,
`
`markets and distributes numerous generic drugs for sale and use throughout the United States,
`
`including in this judicial district.
`
`JURISDICTION AND VENUE
`
`5.
`
`This action arises under the patent laws of the United States of America.
`
`This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331,
`
`1338(a), 2201, and 2202.
`
`6.
`
`This Court has jurisdiction over Mylan because, inter alia, on information
`
`and belief, Mylan is registered to do business in Delaware as a foreign corporation, with filing
`
`number 4809319. Mylan has a designated agent in Delaware for the receipt of service of process
`
`as Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, Delaware
`
`19808. Mylan holds a Pharmacy Wholesale License from the State of Delaware under License
`
`No. A4-0001719. Mylan holds a Distributor/Manufacturer License for Controlled Substances
`
`from the State of Delaware under License No. DM-0007571. Mylan directly or indirectly is in
`
`the business of developing, manufacturing, marketing, importing, offering to sell and selling
`
`pharmaceutical drug products, including generic drug products, throughout the United States,
`
`including this judicial district. Delaware would be a destination of Mylan’s ANDA Products
`
`upon approval and marketing of Mylan’s ANDA Products involved in this action. Mylan’s filing
`
`of its ANDA involved in this action constitutes a formal act that reliably indicates its plans to
`
`engage in marketing of the accused infringing ANDA products in Delaware. This act is
`
`
`ME1 24559871v.1
`
`2
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 3 of 10 PageID #: 3
`
`
`
`sufficient to confer specific jurisdiction over Mylan in Delaware. See Acorda Therapeutics Inc.
`
`v. Mylan Pharms. Inc., 817 F.3d 755 (Fed. Cir. 2016).
`
`7.
`
`On information and belief, Mylan has purposely availed itself of the rights
`
`and benefits of this Court without objecting on the basis of lack of personal jurisdiction when
`
`sued in this Court and through the assertions of counterclaims in suits against it brought in this
`
`Court.
`
`8.
`
`This Court has personal jurisdiction over Mylan by virtue of, inter alia,
`
`the fact that Mylan has availed itself of the rights and benefits of the laws of Delaware by
`
`engaging in systematic and continuous contacts with Delaware.
`
`9.
`
`This Court has personal jurisdiction over Mylan by virtue of, inter alia,
`
`these above-mentioned facts.
`
`10.
`
`Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b) and (c) and
`
`28 U.S.C. § 1400(b).
`
`CLAIM FOR RELIEF – PATENT INFRINGEMENT
`
`11.
`
`Plaintiff NPC holds approved New Drug Application (“NDA”) No.
`
`203985 for AFINITOR Disperz® (everolimus tablets for oral suspension) 2 mg, 3 mg and 5 mg
`
`dosage strengths, which contain the active ingredient everolimus. AFINITOR Disperz®
`
`(everolimus tablets for oral suspension) was approved by the United States Food and Drug
`
`Administration (“FDA”) on August 29, 2012 (2 mg, 3 mg and 5 mg). AFINITOR Disperz®
`
`(everolimus tablets for oral suspension) is indicated for the treatment of: pediatric and adult
`
`patients with tuberous sclerosis complex who have subependymal giant cell astrocytoma that
`
`
`ME1 24559871v.1
`
`3
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 4 of 10 PageID #: 4
`
`
`
`requires therapeutic intervention but cannot be curatively resected. AFINITOR Disperz®
`
`(everolimus tablets for oral suspension) 2 mg, 3 mg, and 5 mg dosage strengths are sold in the
`
`United States by Plaintiff NPC.
`
`12.
`
`Everolimus is known chemically as
`
`(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(1R)-
`
`2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-
`
`15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-
`
`tetraene-2,3,10,14,20-pentaone and also as 40-O-(2-hydroxyethyl)-rapamycin. The chemical
`
`name “(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-
`
`{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-
`
`dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-
`
`16,24,26,28-tetraene-2,3,10,14,20-pentaone” is equivalent to “40-O-(2-hydroxyethyl)-
`
`rapamycin.”
`
`13.
`
`Plaintiff Novartis AG is the owner of United States Letters Patent No.
`
`5,665,772 (“the ’772 patent”). The ’772 patent was duly and legally issued on September 9,
`
`1997.
`
`14.
`
`The ’772 patent claims, inter alia, the compound everolimus and a
`
`pharmaceutical composition containing a therapeutically effective amount of everolimus and a
`
`pharmaceutically acceptable carrier. A true copy of the ’772 patent is attached as Exhibit A.
`
`15.
`
`Plaintiff NPC is the owner of United States Letters Patent No. 8,778,962
`
`(“the ’962 patent”). The ’962 patent was duly and legally issued on July 15, 2014.
`
`
`ME1 24559871v.1
`
`4
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 5 of 10 PageID #: 5
`
`
`
`16.
`
`The ’962 patent claims, inter alia, a method for inhibiting growth of non-
`
`malignant solid tumors of the brain in a subject, said method consisting of administering to said
`
`subject a therapeutically effective amount of everolimus. A true copy of the ’962 patent is
`
`attached as Exhibit B.
`
`17.
`
`Plaintiff Novartis AG is the owner of United States Letters Patent No.
`
`8,617,598 (“the ’598 patent”). The ’598 patent was duly and legally issued on December 31,
`
`2013.
`
`18.
`
`The ’598 patent claims, inter alia, certain pharmaceutical compositions in
`
`the form of a dispersible tablet comprising a solid dispersion of everolimus, a disintegrant and
`
`colloidal silicon dioxide. A true copy of the ’598 patent is attached as Exhibit C.
`
`19.
`
`On information and belief, Mylan submitted to the FDA an abbreviated
`
`new drug application (“ANDA”) under the provisions of 21 U.S.C. § 355(j) seeking approval to
`
`engage in the commercial manufacture, use, offer for sale and sale of everolimus tablets for oral
`
`suspension in 2 mg, 3 mg and 5 mg dosage strengths (the “ANDA Products”) before the
`
`expiration of the ’772, ’962 and ’598 patents.
`
`20.
`
`Plaintiffs received written notification of Mylan’s ANDA containing a §
`
`355(j)(2)(A)(vii)(IV) certification by letter dated February 24, 2017 (“Notice Letter”), which
`
`alleged that claims 1-3 and 7-10 of the ’772 patent are invalid and claims 4-6 of the ’772 patent
`
`will not be infringed by Mylan, claims 1-6 of the ’962 patent are invalid, and claims 1-6 of the
`
`’598 will not be infringed by Mylan. Mylan did not allege non-infringement of claims 1-3 and 7-
`
`10 of the ’772 patent or claims 1-6 of the ’962 patent. Mylan also did not allege that any of the
`
`claims of the ’772, ’962 and ’598 patents were unenforceable.
`
`5
`
`
`ME1 24559871v.1
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 6 of 10 PageID #: 6
`
`
`
`Letter.
`
`21.
`
`22.
`
`This action was commenced within 45 days of receipt of the Mylan Notice
`
`By filing its ANDA under 21 U.S.C. § 355(j) for the purpose of obtaining
`
`approval to engage in the commercial manufacture, use, or sale of Mylan’s ANDA Products
`
`before the expiration of the ’772, ’962 and ’598 patents, Mylan has committed an act of
`
`infringement under 35 U.S.C. § 271(e)(2).
`
`23.
`
`On information and belief, when Mylan filed its ANDA, it was aware of
`
`the ’772, ’962 and ’598 patents and that the filing of its ANDA with the request for its approval
`
`prior to the expiration of the ’772, ’962 and ’598 patents was an act of infringement of those
`
`patents.
`
`24.
`
`On information and belief, the commercial manufacture, use, offer for
`
`sale, or sale in the United States and/or importation into the United States of Mylan’s ANDA
`
`Products will infringe one or more claims of the ’772, ’962 and ’598 patents.
`
`25.
`
`On information and belief, Mylan’s ANDA Products, if approved, will
`
`contain everolimus and be a pharmaceutical composition containing a therapeutically effective
`
`amount of everolimus and a pharmaceutically acceptable carrier. On information and belief, the
`
`commercial manufacture, use, offer for sale, sale and/or importation of Mylan’s ANDA Products
`
`will directly infringe the ’772 patent.
`
`26. Mylan did not deny infringement of claims 1-3 and 7-10 of the ’772 patent
`
`in its Notice Letter.
`
`
`ME1 24559871v.1
`
`6
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 7 of 10 PageID #: 7
`
`
`
`27.
`
`On information and belief, Mylan’s ANDA Products, if approved, will
`
`contain instructions for administering a therapeutically effective amount of everolimus to inhibit
`
`growth of non-malignant solid tumors of the brain in a subject, which administration will
`
`constitute direct infringement of the ’962 patent. On information and belief, if Mylan’s ANDA
`
`Products are approved, Mylan will actively induce, encourage, and abet this infringement with
`
`knowledge of the ’962 patent, and that its acts will induce infringement of the ’962 patent.
`
`28.
`
`On information and belief, if Mylan’s ANDA Products are approved,
`
`Mylan will commercially manufacture, offer for sale and/or sell those products, which will be
`
`specifically labeled for use in a method for inhibiting growth of non-malignant solid tumors of
`
`the brain in a subject, said method consisting of administering to said subject a therapeutically
`
`effective amount of everolimus. On information and belief, if Mylan’s ANDA Products are
`
`approved, those products will constitute a material part of a method for inhibiting growth of non-
`
`malignant solid tumors of the brain in a subject, said method consisting of administering to said
`
`subject a therapeutically effective amount of everolimus. On information and belief, if Mylan’s
`
`ANDA Products are approved, Mylan will contributorily infringe the ’962 patent, and will do so
`
`with knowledge of the ’962 patent, and that its ANDA Products are especially made or especially
`
`adapted for use in infringing the ’962 patent and are not suitable for a substantial noninfringing
`
`use.
`
`29. Mylan did not deny infringement of claims 1-6 of the ’962 patent in its
`
`Notice Letter.
`
`30.
`
`On information and belief, Mylan’s ANDA Products, if approved, will
`
`contain a pharmaceutical composition in the form of a solid dispersion comprising everolimus, a
`
`
`ME1 24559871v.1
`
`7
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 8 of 10 PageID #: 8
`
`
`
`disintegrant and colloidal silicon dioxide. On information and belief, the commercial
`
`manufacture, use, offer for sale, sale and/or importation of Mylan’s ANDA Products will directly
`
`infringe the ’598 patent.
`
`31.
`
`Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4),
`
`including an order of this Court that the effective date of any approval of the ANDA relating to
`
`Mylan’s ANDA Products be a date that is no earlier than March 9, 2020, the expiration of the
`
`’772 patent’s pediatric exclusivity, August 18, 2022, the expiration date of the ’962 patent’s
`
`pediatric exclusivity, and March 27, 2023, the expiration of the ’598 patent’s pediatric
`
`exclusivity, and an award of damages for any commercial sale or use of Mylan’s ANDA
`
`Products and any act committed by Mylan with respect to the subject matter claimed in the ’772,
`
`’598, and ’962 patents, which act is not within the limited exclusions of 35 U.S.C. § 271(e)(1).
`
`32.
`
`On information and belief, Mylan has taken and continues to take active
`
`steps towards the commercial manufacture, use, offer for sale, sale, and/or importation of
`
`Mylan’s ANDA Products, including seeking approval of those products under Mylan’s ANDA.
`
`33.
`
`There is a substantial and immediate controversy between Plaintiffs and
`
`Mylan concerning the ’772, ’962 and ’598 patents. Plaintiffs are entitled to declaratory judgment
`
`under 28 U.S.C. §§ 2201 and 2202 that Mylan will infringe, induce infringement of and/or
`
`contributorily infringe one or more claims of the ’772, ’962 and ’598 patents.
`
`
`ME1 24559871v.1
`
`8
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 9 of 10 PageID #: 9
`
`
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiffs respectfully request the following relief:
`
`A.
`
`Judgment that Mylan has directly infringed, induced infringement of
`
`and/or contributorily infringed one or more claims of the ’772, ’962 and ’598 patents by filing an
`
`ANDA relating to Mylan’s everolimus tablets for oral suspension in 2 mg, 3 mg and 5 mg
`
`dosage strengths;
`
`B.
`
`A permanent injunction restraining and enjoining Mylan and its officers,
`
`agents, attorneys, and employees, and those acting in privity or concert with it, from engaging in
`
`the commercial manufacture, use, offer to sell, or sale in the United States, or importation into
`
`the United States, of Mylan’s everolimus tablets for oral suspension in 2 mg, 3 mg and 5 mg
`
`dosage strengths, as claimed in the ’772, ’962 and ’598 patents;
`
`C.
`
`An order that the effective date of any approval of the ANDA relating to
`
`Mylan’s everolimus tablets for oral suspension in 2 mg, 3 mg and 5 mg dosage strengths be a
`
`date that is not earlier than the expiration of the right of exclusivity under the ’772, ’962 and
`
`’598 patents;
`
`D.
`
`Declaratory judgment that the commercial manufacture, use, offer for sale,
`
`sale, and/or importation of Mylan’s everolimus tablets for oral suspension in 2 mg, 3 mg and 5
`
`mg dosage strengths will directly infringe, induce infringement of and/or contributorily infringe
`
`one or more claims of the ’772, ’962 and ’598 patents;
`
`E.
`
`Damages from Mylan for the infringement, inducement of infringement
`
`and contributory infringement of the ’772, ’962 and ’598 patents;
`
`F.
`
`The costs and reasonable attorney fees of Plaintiffs in this action; and
`
`G.
`
`Such other and further relief as the Court may deem just and proper.
`
`
`ME1 24559871v.1
`
`9
`
`
`
`Case 1:17-cv-00389-RGA Document 1 Filed 04/07/17 Page 10 of 10 PageID #: 10
`
`McCARTER & ENGLISH, LLP
`
`/s/ Daniel M. Silver
`Daniel M. Silver (#4758)
`Benjamin A. Smyth (#5528)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`(302) 984-6300
`dsilver@mccarter.com
`bsmyth@mccarter.com
`
`Attorneys for Plaintiffs
`
`
`
`Dated: April 7, 2017
`
`
`
`
`
`
`
`
`Of Counsel:
`
`Nicholas N. Kallas
`Charlotte Jacobsen
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, New York 10104-3800
`(212) 218-2100
`nkallas@fchs.com
`cjacobsen@fchs.com
`
`
`
`ME1 24559871v.1
`FCHS_WS 13309708v1.doc
`
`10
`
`